Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Alistar A, et al. Among authors: morris bb. Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8. Lancet Oncol. 2017. PMID: 28495639 Free PMC article. Clinical Trial.
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K. Lamar ZS, et al. Among authors: morris bb. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):76-81. doi: 10.1016/j.clml.2015.11.012. Epub 2015 Dec 2. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26725264 Free PMC article.
Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana Prostate Cancer Project (PCaP).
Steck SE, Su LJ, Antwi SO, Morris BB, Crawford B, Adams SA, Hebert JR, Fontham ETH, Bensen JT, Mohler JL, Arab L. Steck SE, et al. Among authors: morris bb. Cancer Causes Control. 2022 Jun;33(6):875-887. doi: 10.1007/s10552-022-01572-z. Epub 2022 Mar 23. Cancer Causes Control. 2022. PMID: 35320830 Free PMC article.
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.
Morris BB, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, Arriola E, Lee MC, Tyson DR, Concannon K, Ramkumar K, Stewart CA, Cardnell RJ, Wang R, Quaranta V, Wang J, Heymach JV, Nabet BY, Shames DS, Gay CM, Byers LA. Morris BB, et al. bioRxiv [Preprint]. 2024 Jul 30:2024.07.29.605595. doi: 10.1101/2024.07.29.605595. bioRxiv. 2024. PMID: 39211077 Free PMC article. Preprint.
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A Jr, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. Stewart CA, et al. Among authors: morris bb. Clin Cancer Res. 2024 Oct 15;30(20):4743-4754. doi: 10.1158/1078-0432.CCR-24-0361. Clin Cancer Res. 2024. PMID: 39150543
31 results